Analyst Summary You Should Be Viewing Today: Cornerstone OnDemand, Inc. (NASDAQ:CSOD), The Advisory Board Company (NASDAQ:ABCO)

Cornerstone OnDemand, Inc. (NASDAQ:CSOD) showed a growth of 0.31% from the market’s prior closing price. That gain sent the price at $41.73 per share as of January 13,2017 when the total trading capacity was lower compared with their three months average volume of 851.31TH shares. The consensus analyst PT for this stock has now been moved to $41.94.

Cornerstone OnDemand, Inc. (CSOD) Price Indications

The firm keeps price-to-earnings ratio at – in 12 months. In last trade, the intraday high was $42.13, putting the share price -12.61% below its 52-week high and trades 87.55% higher from the lowest price they have traded at during the previous year. It turned higher 6.93% from its 50-day simple moving average. The current price is up 3.61% from the average market prices over a 200-day period.

Cornerstone OnDemand, Inc. (NASDAQ:CSOD) Thorough Brokerage Views

There are numerous brokerage names which are spending time researching on this stock. Of them, 0 have a Sell, 2 suggested Buy, 8 said Outperform and 7 called Hold rating for the stock, based on Thomson Reuters I/B/E/S. 1 recommends the stock is “underperforming”. The company has a Consensus Recommendation of 2.39, according to Thomson Reuters data.

On January 13,2017, The Advisory Board Company (NASDAQ:ABCO) closed session down at $41.75 with -0.60%. The institutional holdings in the company makes up – while the Beta factor is 1.14. The stock’s RSI (Relative Strength Index) reached 76.86.

The Advisory Board Company (ABCO) Price Potential

In recent trade, the price was 13.09% up its 200 day moving average and was brought 21.17% up versus its 50-day simple moving average. The stock exchanged hands at a volume of 1.07M shares whereas, the average volume was 542.42K shares. In the past 12 months, the share price floated in the $18.87 -$48.86 range. The market capitalization arrived at market cap 1.69 billion. After the day trading kicked off at $41.25, the stock was seen approaching $41.05 as its bottom price and $42.60 as its intraday high price. In previous session, the price was settled at $42.00.

The Advisory Board Company (NASDAQ:ABCO) Analyst Point of Interest

There were more than a few analysts who recently mentioned the stock in their research. Currently the stock is holding a ‘Buy’ rating from 5 equity analysts. 0 Wall Street brokerages assign ‘Sell’ rating for the firm. 7 analysts are of a belief the stock is a ‘Hold’. ‘Underperform’ verdict was provided by 1 analysts and ‘Overweight’ verdict was shared by 5 analysts. The company has a Mean Recommendation of 2.22 based on a scale of 1-5 provided by Thomson Reuters.

Prominent Analysts Reporting Update: Insulet Corporation (NASDAQ:PODD), Zions Bancorporation (NASDAQ:ZION)

Insulet Corporation (NASDAQ:PODD) showed a growth of 8.52% from the market’s prior closing price. That gain sent the price at $43.55 per share as of January 13,2017 when the total trading capacity was higher compared with their three months average volume of 684.66TH shares. The consensus analyst PT for this stock has now been moved to $43.37.

Insulet Corporation (PODD) Price Indications

The firm keeps price-to-earnings ratio at – in 12 months. In last trade, the intraday high was $44.92, putting the share price -4.50% below its 52-week high and trades 81.91% higher from the lowest price they have traded at during the previous year. It turned higher 18.72% from its 50-day simple moving average. The current price is up 20.78% from the average market prices over a 200-day period.

Insulet Corporation (NASDAQ:PODD) Thorough Brokerage Views

There are numerous brokerage names which are spending time researching on this stock. Of them, 0 have a Sell, 8 suggested Buy, 3 said Outperform and 9 called Hold rating for the stock, based on Thomson Reuters I/B/E/S. 0 recommends the stock is “underperforming”. The company has a Consensus Recommendation of 2.05, according to Thomson Reuters data.

On January 13,2017, Zions Bancorporation (NASDAQ:ZION) closed session up at $43.85 with 2.05%. The institutional holdings in the company makes up 89.40% while the Beta factor is 1.47. The stock’s RSI (Relative Strength Index) reached 58.74.

Zions Bancorporation (ZION) Price Potential

In recent trade, the price was 41.69% up its 200 day moving average and was brought 9.50% up versus its 50-day simple moving average. The stock exchanged hands at a volume of 2.73M shares whereas, the average volume was 3.12M shares. In the past 12 months, the share price floated in the $19.45 -$44.33 range. The market capitalization arrived at market cap 8.96 billion. After the day trading kicked off at $43.29, the stock was seen approaching $43.03 as its bottom price and $44.32 as its intraday high price. In previous session, the price was settled at $42.97.

Zions Bancorporation (NASDAQ:ZION) Analyst Point of Interest

There were more than a few analysts who recently mentioned the stock in their research. Currently the stock is holding a ‘Buy’ rating from 5 equity analysts. 0 Wall Street brokerages assign ‘Sell’ rating for the firm. 15 analysts are of a belief the stock is a ‘Hold’. ‘Underperform’ verdict was provided by 0 analysts and ‘Overweight’ verdict was shared by 7 analysts. The company has a Mean Recommendation of 2.37 based on a scale of 1-5 provided by Thomson Reuters.

Looking At Recent Analyst Recommendations: Xylem Inc. (NYSE:XYL), CyrusOne Inc. (NASDAQ:CONE)

Xylem Inc. (NYSE:XYL) showed a growth of 0.95% from the market’s prior closing price. That gain sent the price at $48.76 per share as of January 13,2017 when the total trading capacity was higher compared with their three months average volume of 1.41M shares. The consensus analyst PT for this stock has now been moved to $53.31.

Xylem Inc. (XYL) Price Indications

The firm keeps price-to-earnings ratio at 27.06 in 12 months. In last trade, the intraday high was $49.15, putting the share price -11.33% below its 52-week high and trades 56.15% higher from the lowest price they have traded at during the previous year. It turned lower -4.20% from its 50-day simple moving average. The current price is up 2.58% from the average market prices over a 200-day period.

Xylem Inc. (NYSE:XYL) Thorough Brokerage Views

There are numerous brokerage names which are spending time researching on this stock. Of them, 0 have a Sell, 5 suggested Buy, 3 said Outperform and 6 called Hold rating for the stock, based on Thomson Reuters I/B/E/S. 0 recommends the stock is “underperforming”. The company has a Consensus Recommendation of 2.07, according to Thomson Reuters data.

On January 13,2017, CyrusOne Inc. (NASDAQ:CONE) closed session down at $48.93 with -0.18%. The institutional holdings in the company makes up 97.40% while the Beta factor is 0.84. The stock’s RSI (Relative Strength Index) reached 75.87.

CyrusOne Inc. (CONE) Price Potential

In recent trade, the price was 3.37% up its 200 day moving average and was brought 12.62% up versus its 50-day simple moving average. The stock exchanged hands at a volume of 848.64TH shares whereas, the average volume was 1.33M shares. In the past 12 months, the share price floated in the $31.37 -$56.07 range. The market capitalization arrived at market cap 4.09 billion. After the day trading kicked off at $49.00, the stock was seen approaching $48.77 as its bottom price and $49.39 as its intraday high price. In previous session, the price was settled at $49.02.

CyrusOne Inc. (NASDAQ:CONE) Analyst Point of Interest

There were more than a few analysts who recently mentioned the stock in their research. Currently the stock is holding a ‘Buy’ rating from 9 equity analysts. 0 Wall Street brokerages assign ‘Sell’ rating for the firm. 3 analysts are of a belief the stock is a ‘Hold’. ‘Underperform’ verdict was provided by 0 analysts and ‘Overweight’ verdict was shared by 6 analysts. The company has a Mean Recommendation of 1.67 based on a scale of 1-5 provided by Thomson Reuters.

Franklin Resources, Inc. (NYSE:BEN) Trades Higher, 8 Hold Recommendations

Franklin Resources, Inc. (NYSE:BEN) registered a 0.05% increase, still its new closing price is 34.67% up from the company’s 1 year high of 41.97.It posted -0.61% losses in previous 5 sessions and is now the subject of 8 analysts who together assign a hold rating on stock. 3 of Wall Street analysts have an underperform rating; the 1 sells versus 2 buy or better ratings. The 14 stock analysts following this company have an average price target at $38.33, with individual PT in the $32.00-$45.00 range. The shares moved at $40.50, implying that brokerage firms see shares gaining about 23.91% in twelve months time.

Franklin Resources, Inc. (BEN) SEC Form 4 News

The stock is getting much attention these days as insiders are offloading shares while they posted a 2.32% rise year to date. A EVP and CFO at Franklin Resources, Inc. (BEN) offloaded shares in a transaction closed on Friday December 16, 2016. LEWIS KENNETH A sold 1,866 shares in the company at $39.25 each and collected $73,000 in proceeds. LEWIS KENNETH A now owns 158,840 shares in the company after this transaction. A EVP and CFO in the company, LEWIS KENNETH A, disclosed a transaction on Thursday December 08, 2016 that ended up generating $177,000 from the sale of 4,230 shares at $41.96 per share.

Franklin Resources, Inc. (NYSE:BEN) Upcoming Results on Tap

Franklin Resources, Inc. will next provide financial results for the December 2017 quarter. Stock analysts expect it to report per-share earnings of $0.69 in that period. Sales during the quarter are predicted to arrive at $1.55 billion.

Earnings surprise history: Last quarter, the company posted approximately $1.61 billion in revenue and EPS of $0.82. The mean forecast was for $1.63 billion and $0.69 a share, respectively. One quarter earlier, revenue for the stock was at $1.63 billion, with earnings at $0.77/share.

Franklin Resources, Inc. (BEN) Brokerage Update

Franklin Resources, Inc. (BEN) is in Deutsche Bank’s research list so their analyst rating change is noteworthy. These shares were downgraded to Sell from Hold by Deutsche Bank, according to news reported on Thursday November 10, 2016.Another important research note was issued by UBS on Thursday November 10, 2016.The firm upgraded BEN to Neutral from Sell. Over the last six months and over the last three months, the shares of Franklin Resources, Inc. (BEN), have changed 17.94% and 18.32%, respectively.

Franklin Resources, Inc. (NYSE:BEN) on January 13, 2017 reported that it will release its first fiscal quarter 2017 operating results on Friday, January 27, 2017 at approximately 8:30 a.m. Eastern Time.  A written commentary on the results by Chairman and CEO Greg Johnson and CFO and Executive Vice President Ken Lewis will be available at approximately 8:30 a.m. Eastern Time. Johnson and Lewis will also lead a live teleconference at 11:00 a.m. Eastern Time to answer questions of a material nature.

Constellation Brands, Inc. (NYSE:STZ) Target Price Means Stock Is Worth $175.13

Constellation Brands, Inc. (NYSE:STZ) registered a 1.19% increase, still its new closing price is 15.49% up from the company’s 1 year high of 173.12.It posted -0.11% losses in previous 5 sessions and is now the subject of 5 analysts who together assign a hold rating on stock. 1 of Wall Street analysts have an underperform rating; the 0 sells versus 5 buy or better ratings. The 18 stock analysts following this company have an average price target at $175.13, with individual PT in the $132.00-$200.00 range. The shares moved at $149.28, implying that brokerage firms see shares gaining about 5.21% in twelve months time.

Constellation Brands, Inc. (STZ) SEC Form 4 News

The stock is getting much attention these days as insiders are offloading shares while they posted a -2.63% fall year to date. A Exec. VP & Gen. Counsel at Constellation Brands, Inc. (STZ) offloaded shares in a transaction closed on Thursday August 25, 2016. MULLIN THOMAS J sold 9,516 shares in the company at $166.42 each and collected $1,583,001 in proceeds. MULLIN THOMAS J now owns 88,602 shares in the company after this transaction. A Executive VP, Chief HR Officer in the company, Kane Thomas Michael, disclosed a transaction on Thursday July 28, 2016 that ended up generating $1,142,001 from the sale of 7,000 shares at $163.26 per share.

Constellation Brands, Inc. (NYSE:STZ) Upcoming Results on Tap

Constellation Brands, Inc. will next provide financial results for the May 2017 quarter. Stock analysts expect it to report per-share earnings of $1.88 in that period. Sales during the quarter are predicted to arrive at $1.98 billion.

Earnings surprise history: Last quarter, the company posted approximately $1.81 billion in revenue and EPS of $1.96. The mean forecast was for $1.81 billion and $1.72 a share, respectively. One quarter earlier, revenue for the stock was at $2.02 billion, with earnings at $1.77/share.

Constellation Brands, Inc. (STZ) Brokerage Update

Constellation Brands, Inc. (STZ) is in BofA/Merrill’s research list so their analyst rating change is noteworthy. These shares were upgraded to Buy from Underperform by BofA/Merrill, according to news reported on Wednesday January 04, 2017.Another important research note was issued by Sun Trust Rbsn Humphrey on Monday March 14, 2016.The firm upgraded STZ to Buy from Neutral. Over the last six months and over the last three months, the shares of Constellation Brands, Inc. (STZ), have changed -8.01% and -11.42%, respectively.

January 16, 2017 — Constellation Brands, Inc. (NYSE:STZ) has announced Franciscan Estate Winery in Napa Valley, California, as the winner of the company`s 2016 Internal Sustainability Award. The award, given annually by Constellation to one of its facilities, recognizes Franciscan Estate`s continued commitment to minimizing its environmental impact.

Franciscan Estate`s recent sustainability achievements include:

  • Collaborator on a project to restore nine miles of the Napa River.
  • Reduced landscaping water usage by nearly 2 million gallons per year since 2014 by utilizing processed wastewater for drip irrigation, implementing landscaping redesigns and planting drought resistant plants.
  • Highly engaged “Green” and “Blue” teams help solve sustainability and water challenges. One of the many improvements to come from these teams is an 80% reduction in water use for tank sanitation.
  • Continued energy efficiency efforts in administrative areas, including installation of ENERGY STAR® products, programmable thermostats and electricity misers.

MetLife, Inc. (NYSE:MET) at $54.31: How much growth it can achieve

MetLife, Inc. (NYSE:MET) registered a 0.74% increase, still its new closing price is 59.42% up from the company’s 1 year high of 58.09.It posted 0.24% gains in previous 5 sessions and is now the subject of 7 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 4 buy or better ratings. The 17 stock analysts following this company have an average price target at $60.46, with individual PT in the $54.00-$67.00 range. The shares moved at $54.31, implying that brokerage firms see shares gaining about 29.40% in twelve months time.

MetLife, Inc. (MET) SEC Form 4 News

The stock is getting much attention these days as insiders are offloading shares while they posted a 0.78% rise year to date. A EVP & Chief Accounting Officer at MetLife, Inc. (MET) offloaded shares in a transaction closed on Friday December 23, 2016. Carlson Peter M sold 23,636 shares in the company at $54.32 each and collected $1,283,001 in proceeds. Carlson Peter M now owns 29,914 shares in the company after this transaction. A EVP, Global Employee Benefits in the company, Morris Maria R, disclosed a transaction on Thursday December 01, 2016 that ended up generating $121,001 from the sale of 2,200 shares at $55.45 per share.

MetLife, Inc. (NYSE:MET) Upcoming Results on Tap

MetLife, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $1.32 in that period. Sales during the quarter are predicted to arrive at $17.24 billion.

Earnings surprise history: Last quarter, the company posted approximately $18.11 billion in revenue and EPS of $1.28. The mean forecast was for $17.18 billion and $1.14 a share, respectively. One quarter earlier, revenue for the stock was at $16.96 billion, with earnings at $0.83/share.

MetLife, Inc. (MET) Brokerage Update

MetLife, Inc. (MET) is in Standpoint Research’s research list so their analyst rating change is noteworthy. These shares were downgraded to Hold from Buy by Standpoint Research, according to news reported on Friday December 09, 2016.Another important research note was issued by FBR & Co. on Monday November 28, 2016.The firm downgraded MET to Mkt Perform from Outperform. Over the last six months and over the last three months, the shares of MetLife, Inc. (MET), have changed 29.76% and 17.36%, respectively.

MetLife, Inc. (NYSE:MET) on January 6, 2017 announced that its board of directors has declared a first quarter 2017 common stock dividend of $0.40 per share. The dividend will be payable on March 13, 2017, to shareholders of record as of Feb. 6, 2017. MetLife, Inc. (MET), through its subsidiaries and affiliates (“MetLife”), is one of the largest life insurance companies in the world. Founded in 1868, MetLife is a global provider of life insurance, annuities, employee benefits and asset management. Serving approximately 100 million customers, MetLife has operations in nearly 50 countries and holds leading market positions in the United States, Japan, Latin America, Asia, Europe and the Middle East.

Yahoo! Inc. (NASDAQ:YHOO) Insider Transactions Are in the Air

Yahoo! Inc. (NASDAQ:YHOO) registered a 0.38% increase, still its new closing price is 61.64% up from the company’s 1 year high of 44.92.It posted 2.52% gains in previous 5 sessions and is now the subject of 18 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 5 buy or better ratings. The 29 stock analysts following this company have an average price target at $45.68, with individual PT in the $32.00-$55.00 range. The shares moved at $42.27, implying that brokerage firms see shares gaining about 39.41% in twelve months time.

Yahoo! Inc. (YHOO) SEC Form 4 News

The stock is getting much attention these days as insiders are offloading shares while they posted a 9.31% rise year to date. A Chief Revenue Officer at Yahoo! Inc. (YHOO) offloaded shares in a transaction closed on Tuesday January 10, 2017. Utzschneider Lisa sold 410 shares in the company at $41.76 each and collected $17,000 in proceeds. Utzschneider Lisa now owns 583,798 shares in the company after this transaction. A Chief Revenue Officer in the company, Utzschneider Lisa, disclosed a transaction on Friday December 30, 2016 that ended up generating $26,000 from the sale of 683 shares at $38.72 per share.

Yahoo! Inc. (NASDAQ:YHOO) Upcoming Results on Tap

Yahoo! Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $0.15 in that period. Sales during the quarter are predicted to arrive at $1.2 billion.

Earnings surprise history: Last quarter, the company posted approximately $1.31 billion in revenue and EPS of $0.20. The mean forecast was for $1.3 billion and $0.14 a share, respectively. One quarter earlier, revenue for the stock was at $1.31 billion, with earnings at $0.09/share.

Yahoo! Inc. (YHOO) Brokerage Update

Yahoo! Inc. (YHOO) is in Jefferies’s research list so their analyst rating change is noteworthy. These shares were downgraded to Hold from Buy by Jefferies, according to news reported on Friday October 21, 2016.Another important research note was issued by Needham on Tuesday October 18, 2016.The firm downgraded YHOO to Hold from Buy. Over the last six months and over the last three months, the shares of Yahoo! Inc. (YHOO), have changed 12.06% and 1.56%, respectively.

Allergan plc (NYSE:AGN) Earns 5 Analysts Hold Rating

Allergan plc (NYSE:AGN) registered a -0.05% decrease, still its new closing price is 17.15% up from the company’s 1 year high of 301.98.It posted -1.34% losses in previous 5 sessions and is now the subject of 5 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 8 buy or better ratings. The 22 stock analysts following this company have an average price target at $260.11, with individual PT in the $202.00-$400.00 range. The shares moved at $216.14, implying that brokerage firms see shares losing about -27.74% in twelve months time.

Allergan plc (AGN) SEC Form 4 News

The stock is getting much attention these days as insiders are offloading shares while they posted a 2.92% rise year to date. A Director at Allergan plc (AGN) offloaded shares in a transaction closed on Thursday December 08, 2016. Basgoz Nesli sold 500 shares in the company at $188.72 each and collected $94,000 in proceeds. Basgoz Nesli now owns 5,515 shares in the company after this transaction. A CEO and President in the company, SAUNDERS BRENT L, disclosed a transaction on Monday November 21, 2016 that ended up paying $992,001 from the purchase of 5,250 shares at $189.13 per share.

Allergan plc (NYSE:AGN) Upcoming Results on Tap

Allergan plc will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $3.94 in that period. Sales during the quarter are predicted to arrive at $3.58 billion.

Earnings surprise history: Last quarter, the company posted approximately $3.62 billion in revenue and EPS of $3.32. The mean forecast was for $3.68 billion and $3.56 a share, respectively. One quarter earlier, revenue for the stock was at $3.68 billion, with earnings at $3.35/share.

Allergan plc (AGN) Brokerage Update

Allergan plc (AGN) is in Mizuho’s research list so their analyst rating change is noteworthy. These shares were upgraded to Buy from Neutral by Mizuho, according to news reported on Friday August 19, 2016.Another important research note was issued by Piper Jaffray on Monday April 18, 2016.The firm downgraded AGN to Neutral from Overweight. Over the last six months and over the last three months, the shares of Allergan plc (AGN), have changed -10.87% and -6.98%, respectively.

On January 17, 2017, Allergan plc (NYSE:AGN) and Gedeon Richter Plc. announced positive results from Venus II, the second of two pivotal phase III clinical trials evaluating the efficacy and safety of ulipristal acetate in women with abnormal bleeding due to uterine fibroids.  A new drug application filing for ulipristal acetate is planned for the second half of 2017.

The study included 432 U.S. patients with 162 and 157 patients randomized to ulipristal acetate 5 and 10 mg respectively, and 113 to placebo. The average age of patients enrolled was 41 years and 67 percent of enrolled patients were Black/African Americans. The study met all the co-primary and secondary endpoints with both ulipristal treatment arms achieving statistically significant results over placebo (p<0.0001). The co-primary efficacy endpoints were percentage of patients with absence of uterine bleeding and time to absence of uterine bleeding on treatment during Treatment Course One (12-week duration).  Significantly more patients in the 10 mg group (54.8%) and the 5 mg group (42.0%) achieved absence of bleeding compared to placebo (0%).

The secondary efficacy endpoints were the percentage of patients with absence of uterine bleeding from Day 11 to end of the first treatment course; the percentage of patients with absence of uterine bleeding after the second treatment course; time to absence of uterine bleeding on treatment during treatment course two; and the change from baseline in the UFS-QOL revised Activities subscale at the end of the first treatment course.

More patients in the 10 mg group (55.4%) and the 5 mg group (34.6%) achieved absence of bleeding within 10 days after treatment initiation in Treatment Course One compared to placebo (0.0%). Significantly more patients in the 10 mg group (57.3%) and the 5 mg group (40.5%) achieved absence of bleeding compared to placebo (8.0%) in Treatment Course Two.  The improvement from baseline in the UFS-QOL revised activities subscale was significantly greater in the 10 mg group (56.7%) and the 5 mg group (48.3%) compared to placebo (13.0%).

The UFS-QOL is a validated fibroid-specific symptom and health-related quality of life instrument. This questionnaire is an established instrument to assess disease impact on the well-being of women with uterine fibroids.

salesforce.com, inc. (NYSE:CRM) Insider Transactions Are in the Air

salesforce.com, inc. (NYSE:CRM) registered a 0.57% increase, still its new closing price is 43.80% up from the company’s 1 year high of 84.48.It posted 2.49% gains in previous 5 sessions and is now the subject of 3 analysts who together assign a hold rating on stock. 1 of Wall Street analysts have an underperform rating; the 0 sells versus 20 buy or better ratings. The 48 stock analysts following this company have an average price target at $94.44, with individual PT in the $64.00-$110.00 range. The shares moved at $75.64, implying that brokerage firms see shares gaining about 3.52% in twelve months time.

salesforce.com, inc. (NYSE:CRM) Upcoming Results on Tap

salesforce.com, inc. will next provide financial results for the April 2017 quarter. Stock analysts expect it to report per-share earnings of $0.30 in that period. Sales during the quarter are predicted to arrive at $2.37 billion.

Earnings surprise history: Last quarter, the company posted approximately $2.14 billion in revenue and EPS of $0.24. The mean forecast was for $2.12 billion and $0.21 a share, respectively. One quarter earlier, revenue for the stock was at $2.04 billion, with earnings at $0.24/share.

salesforce.com, inc. (CRM) Brokerage Update

salesforce.com, inc. (CRM) is in Pivotal Research Group’s research list so their analyst rating change is noteworthy. These shares were downgraded to Hold from Buy by Pivotal Research Group, according to news reported on Thursday January 12, 2017.Another important research note was issued by Credit Agricole on Wednesday February 10, 2016.The firm upgraded CRM to Buy from Outperform. Over the last six months and over the last three months, the shares of salesforce.com, inc. (CRM), have changed -7.08% and 7.09%, respectively.

salesforce.com, inc. (NYSE:CRM) on January 16, 2017 announced that Salesforce Chairman and CEO Marc Benioff will participate at the World Economic Forum Annual Meeting taking place in Davos, Switzerland, from January 17-20, 2017. At the event, Benioff will participate in the following panel discussions:

  • Tuesday, January 17: Benioff will join Mary Barra, Chairman and CEO, General Motors; Shu Yinbiao, Chairman, State Grid Corporation of China; and Dr. Vishal Sikka, CEO, Infosys, in a panel discussion moderated by Ngaire Woods, Dean, Blavatnik School of Government at Oxford University. The session will begin at approximately 6:00 pm CET. A live webcast of the event will be available at: http://wef.ch/82968.
  • Thursday, January 19: Benioff will moderate a panel discussion with Mary Barra, Chairman and CEO, General Motors; Peter Maurer, President, International Committee, Red Cross; Paul Polman, CEO, Unilever; Bernard J Tyson, Chairman and CEO, Kaiser Permanente; and will.i.am, Founder and President, i.am.angel Foundation. The session will begin at approximately noon CET. A video recording of the panel will be available at 9:00 am PST on Friday, January 20, on Salesforce LIVE: https://www.salesforce.com/video/430986/.

The Blackstone Group L.P. (NYSE:BX) PT Suggests Stock Is Worth Around $33.85

The Blackstone Group L.P. (NYSE:BX) registered a -0.36% decrease, still its new closing price is 43.67% up from the company’s 1 year high of 31.16.It posted -1.38% losses in previous 5 sessions and is now the subject of 3 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 5 buy or better ratings. The 15 stock analysts following this company have an average price target at $33.85, with individual PT in the $29.00-$38.00 range. The shares moved at $30.09, implying that brokerage firms see shares gaining about 25.01% in twelve months time.

The Blackstone Group L.P. (BX) SEC Form 4 News

The stock is getting much attention these days as insiders are offloading shares while they posted a 11.32% rise year to date. A Chief Legal Officer at The Blackstone Group L.P. (BX) offloaded shares in a transaction closed on Monday December 19, 2016. Finley John G sold 10,000 shares in the company at $29 each and collected $290,000 in proceeds. Finley John G now owns 140,745 shares in the company after this transaction. A Principal Accounting Officer in the company, SKERO KATHLEEN, disclosed a transaction on Wednesday September 07, 2016 that ended up generating $304,001 from the sale of 11,500 shares at $26.51 per share.

The Blackstone Group L.P. (NYSE:BX) Upcoming Results on Tap

The Blackstone Group L.P. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $0.70 in that period. Sales during the quarter are predicted to arrive at $1.62 billion.

Earnings surprise history: Last quarter, the company posted approximately $1.39 billion in revenue and EPS of $0.57. The mean forecast was for $1.34 billion and $0.48 a share, respectively. One quarter earlier, revenue for the stock was at $1.17 billion, with earnings at $0.44/share.

The Blackstone Group L.P. (BX) Brokerage Update

The Blackstone Group L.P. (BX) is in Deutsche Bank’s research list so their analyst rating change is noteworthy. These shares were downgraded to Hold from Buy by Deutsche Bank, according to news reported on Friday March 11, 2016.Another important research note was issued by Oppenheimer on Friday October 16, 2015.The firm upgraded BX to Outperform from Perform. Over the last six months and over the last three months, the shares of The Blackstone Group L.P. (BX), have changed 24.04% and 28.38%, respectively.

The Blackstone Group L.P. (NYSE:BX) on January 7, 2017 announced that it will host its fourth quarter and full year 2016 investor conference call on Thursday, January 26, 2017 at 11:00 a.m. ET. Steve Schwarzman, Chairman, Chief Executive Officer and Co-Founder; Tony James, President and Chief Operating Officer; Michael Chae, Chief Financial Officer; Joan Solotar, Head of Multi-Asset Investing and External Relations; and Weston Tucker, Head of Investor Relations, will review Blackstone’s fourth quarter and full year 2016 results.